期刊
ACS INFECTIOUS DISEASES
卷 2, 期 10, 页码 726-733出版社
AMER CHEMICAL SOC
DOI: 10.1021/acsinfecdis.6b00130
关键词
influenza A virus; M2 proton channel; M2-S31N inhibitor
资金
- University of Arizona
- PhRMA Foundation Research Starter Grant in Pharmacology and Toxicology
- NIH [AI119187]
Despite the existence of flu vaccines and small molecule antiviral drugs, influenza virus infection remains a public health concern that warrants immediate attention. As resistance to the only orally bioavailable drug, oseltamivir, has been continuously reported, there is a clear need to develop the next-generation of anti-influenza drugs. We chose the influenza A virus M2-S31N mutant proton channel as the drug target to address this need as it is one of the most conserved viral proteins and persist in >95% of currently circulating influenza A viruses. In this study, we report the development of a late-stage diversification strategy for the expeditious synthesis of M2-S31N inhibitors. The channel blockage and antiviral activity of the synthesized compounds were tested in two-electrode voltage clamp assays and antiviral assays, respectively. Several M2-S31N inhibitors were identified to have potent M2-S31N channel blockage and micromolar antiviral efficacy against several M2-S31N-containing influenza A viruses.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据